The company’s net income and diluted earnings per share for the 2009 second quarter were $1.27 billion and $0.94 respectively, as compared to $1.12 billion and $0.83 respectively, for the 2008 second quarter. The net revenue for the quarter was recorded at $5.69 million as compared to last years $5.94 million.
Bernard Poussot, chairman, president and CEO of Wyeth, said: Wyeth’s results reflect the ongoing strength of our biotechnology and vaccine franchises Enbrel and Prevnar and our Nutritionals products, all of which performed strongly around the world.
Execution of our medical innovation strategy led to positive revenue growth in constant dollar terms. Diluted earnings per share, excluding certain significant items, increased 8%. Based on this outcome we are raising full year earnings guidance. We remain focused on delivering strong performance as we work with Pfizer toward the successful integration of our two companies, he added.